Phase 2 Trial

AnaptysBio Inc (NASDAQ: ANAB) has announced updated data from the GALLOP Phase 2 trial of imsidolimab in generalized pustular psoriasis (GPP). GPP is a rare and extreme form of psoriasis characterized by the presence of sterile pustules. The 16-week data were presented at the 2021...

CTI BioPharma Corp (NASDAQ: CTIC) has announced topline results from the PRE-VENT trial of pacritinib in hospitalized COVID-19 patients. The final PRE-VENT analysis was conducted following the randomization of 200 patients.  Pacritinib/standard of care, compared to placebo/...

Xenon Pharmaceuticals Inc (NASDAQ: XENE) has reported topline results from the Phase 2b X-TOLE trial evaluating XEN1101 as an adjunctive treatment in adult patients with focal epilepsy. The trial met its primary efficacy endpoint with XEN1101, demonstrating a statistically...

Johnson & Johnson's (NYSE: JNJ) Janssen announced respiratory syncytial virus (RSV) vaccine candidate's efficacy as high as 80% in preventing severe infections in a mid-stage clinical trial. Related: Pfizer Starts Late-Stage Trial For RSV Vaccine Candidate...

Eli Lilly And Co (NYSE: LLY) has posted new data from the Phase 2 study of mirikizumab in moderately to severely active ulcerative colitis (UC) patients. Related: Eli Lilly's Mirikizumab Shows Mucosal Healing In Ulcerative Colitis Maintained For Up To One Year. Patients taking...

Precigen Inc's (NASDAQ: PGEN) subsidiary Precigen ActoBio has announced additional interim data from Phase 1b/2a study of AG019 ActoBiotics for recent-onset type 1 diabetes (T1D). Related: Precigen Stock Surges On Positive AG019 Data for Chronic Treatment Of Type...

BioNTech SE (NASDAQ: BNTX) has dosed the first patient with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in Phase 2 clinical trial.  The trial plans to enroll about 200 patients. The open-label Phase 2 trial is investigating BNT122 in stage 2/3...

Minerva Neurosciences Inc (NASDAQ: NERV) announced results from a bioequivalence study comparing roluperidone formulations used in Phase 2b and Phase 3 trials and the planned commercial formulation.  Related Link: Minerva's Schizophrenia Candidate Shows Long Term...

AIM ImmunoTech Inc (NYSE: AIM) has signed a Clinical Trial Agreement with hVIVO for Phase 2a Human Challenge Trial (HCT) for intranasal Ampligen as prophylaxis against respiratory viruses. The HCT will test Ampligen as a potential intranasal prophylactic using a human rhinovirus (...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Roche Holdings AG (OTC: RHHBY) announced positive data from Phase 2/3 2066 study of Ronapreve (casirivimab and imdevimab) or REGN-COV in hospitalized COVID-19 patients.  Related: WHO Backs Regeneron COVID-19...

Editas Medicine Inc (NASDAQ: EDIT) has announced initial clinical data from the ongoing Phase 1/2 BRILLIANCE trial of EDIT-101 for blindness due to Leber congenital amaurosis 10 (LCA10), a CEP290-related retinal degenerative disorder.  Related Link: Editas Medicine...

Adagio Therapeutics Inc (NASDAQ: ADGI) has announced new data from its COVID-19 antibody program.  Related Link: Adagio Therapeutics To Expand Late-Stage COVID-19 Antibody Trial. The Company is evaluating ADG20 in Phase 1 single ascending dose study of ADG20 ex vivo...

Graybug Vision Inc (NASDAQ: GRAY) has provided a full-data analysis from the 18-month Phase 2b ALTISSIMO trial of GB-102 for wet age-related macular degeneration (wet AMD). GB-102 is Graybug's proprietary formulation of sunitinib malate injected twice a year intravitreally. Related Link:...

The Center for Drug Evaluation of China National Medical Products Administration has signed off I-Mab's (NASDAQ: IMAB) IND application to initiate a Phase 2 trial for enoblituzumab in solid tumors. The trial will evaluate enoblituzumab combined with Merck & Co Inc's...

Valneva SE (NASDAQ: VALN) and Pfizer Inc (NYSE: PFE) have announced more positive Phase 2 results, including the booster response, for their Lyme disease vaccine candidate VLA15. The 246-subject study is evaluating the immunogenicity and safety of VLA15 in a Month 0-2-6...